Oncoinvent ASA: Grant of share options to new CFO

13 Jan 2026 08:13 CET

Oslo, Norway, 13 January 2026: Reference is made to the announcement made by
Oncoinvent ASA ("Oncoinvent" or the "Company") 31 October 2025 regarding the
appointment of Ramzi Amri as the new CEO of the Company as of January 2026. The
Board of Directors has resolved to grant Ramzi Amri 5,430,000 share options in
the Company under the Company's long term incentive program, each with a strike
price of NOK 0.4671, equal to the volume weighted average share price the last
day before the grant. Following the grant of the 5,430,000 share options
referred to above, Ramzi Amri hold no shares and 5,430,000 options in the
Company.

Each option, when exercised, will give the right to acquire one share in the
Company. The options are granted without consideration. Pursuant to the vesting
schedule, 25% of the options will vest 12 months after the day of grant (as long
as the option holder is still employed). Thereafter, 1/36 of the remaining
options will vest each month as long as the option holder is still employed,
with the first 1/36 vesting 13 months after the day of grant. Options that have
not been exercised will lapse 7 years after the date of grant.

The number of options and strike price in this grant will be adjusted when the
reverse share split approved in the Extraordinary General Meeting 8 January 2026
is effective.

The board considers an option program as an important element in attracting and
retaining employees to foster long-term success. The board considers the option
program terms and allocation to be at the market for comparable peers.

PDMR notification Ramzi
Amri (https://mb.cision.com/Public/15728/4291457/b191b8e027c5d3cc.pdf)

This information is subject to the disclosure requirements pursuant to article
19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial is currently ongoing
in the US, UK and Europe. Early clinical efficacy data are highly encouraging,
and no serious toxicity or safety concerns have been reported to date. The
Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art
manufacturing facility to produce drug products for clinical trials in Nydalen,
Oslo. Oncoinvent is listed on the Oslo Stock Exchange.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local
treatment of cancer that has spread to body cavities. It consists of calcium
carbonate microparticles containing the radioactive material radium-224. The
mode of action is the decay of radium-224 emitting alpha-particles, a highly
potent form of ionizing radiation. Radspherin® is investigated in clinical
studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer
and it is administered intraperitoneally after surgical resection with removal
of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These forward
-looking statements represent Oncoinvent's expectations as of the date of this
press release, and Oncoinvent disclaims any obligation to update the forward
-looking statements. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual results to differ
materially, including with respect to whether the results of clinical or other
studies will support the use of our product offerings, the impact of results of
such studies, our expectations of the reliability, accuracy and performance of
our tests, or of the benefits of our tests and product offerings to patients,
providers and payers.

More information:
Access the news on Oslo Bors NewsWeb site

663505_Attachment_PDMR_form_Ramzi_Amri.pdf